Advertisement

Follow us on Twitter @CIR_AACR!

From the Current Issue

  • Research Articles | AuthorChoice
    Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes
    Christof C. Smith, Shengjie Chai, Amber R. Washington, Samuel J. Lee, Elisa Landoni, Kevin Field, Jason Garness, Lisa M. Bixby, Sara R. Selitsky, Joel S. Parker, Barbara Savoldo, Jonathan S. Serody and Benjamin G. Vincent
    Cancer Immunol Res October 1 2019 7 (10) 1591-1604; DOI:10.1158/2326-6066.CIR-19-0155

    A machine-learning algorithm was developed for predicting immunogenic tumor-specific antigens (TSAs). This tool was demonstrated to: (i) predict therapeutically relevant TSAs, (ii) identify genomic signatures correlated with TSA immunogenicity, and (iii) identify out-of-frame TSAs that promote antitumor immunity.

  • Research Articles
    Mirc11 Disrupts Inflammatory but Not Cytotoxic Responses of NK Cells
    Arash Nanbakhsh, Anupallavi Srinivasamani, Sandra Holzhauer, Matthew J. Riese, Yongwei Zheng, Demin Wang, Robert Burns, Michael H. Reimer, Sridhar Rao, Angela Lemke, Shirng-Wern Tsaih, Michael J. Flister, Shunhua Lao, Richard Dahl, Monica S. Thakar and Subramaniam Malarkannan
    Cancer Immunol Res October 1 2019 7 (10) 1647-1662; DOI:10.1158/2326-6066.CIR-18-0934

    The microRNA cluster Mirc11 regulates antitumor responses by targeting ubiquitin modifiers. Absence of Mirc11 led to deubiquitylation of scaffolding K63 and the addition of degradative K48 moieties on TRAF6, ultimately reducing NF-κB and AP1-mediated inflammatory cytokine production.

  • Research Articles
    CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL
    Renée Bouwstra, Yuan He, Janneke de Boer, Hilde Kooistra, Ewa Cendrowicz, Rudolf S.N. Fehrmann, Emanuele Ammatuna, Christine zu Eulenburg, Marcel Nijland, Gerwin Huls, Edwin Bremer and Tom van Meerten
    Cancer Immunol Res October 1 2019 7 (10) 1663-1671; DOI:10.1158/2326-6066.CIR-18-0781

    High CD47 expression impacts survival of patients with non-germinal center, but not germinal center, diffuse large B-cell lymphoma treated with rituximab plus standard chemotherapy. Blocking CD47 in vitro enhanced phagocytosis of rituximab-mediated phagocytosis in only non-GCB cell lines.

OnlineFirst Articles

Load more
Advertisement

Back to top